Evidence map›Paper›PMID 40223933›Full record

ArticleFrontiers in pharmacology2025

Integrative analysis of anti-breast CancerPotential of metabolites from

Yuexing Ma, Haoyi Zheng, Simin Liu, En Yuan, Xin Qiao, Zhang Dai, Wenli Wu, Rongbin Pan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuexing MaCollege of Chinese Medicine, China Pharmaceutical University, Nanjing, Jiangsu, China.
Haoyi ZhengJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Simin LiuJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
En YuanJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Xin QiaoJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Zhang DaiJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Wenli WuJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Rongbin PanJiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The Tibetan medicinal botanical drug Taoerqi has long been recognized for its anti-inflammatory, antibacterial, and tumor-inhibitory properties. Methods: Botanical drug focuses on the isolation and characterization of secondary metabolites from Results: The secondary metabolites from Discussion: This study provides insights into the therapeutic potential of these metabolites and lays the groundwork for future preclinical and

Indexed as

breast cancerCancerPotentialendophytic metabolitesPseudomonas frederiksbergensisTaoerqi

Identifiers

PMID40223933
PMCPMC11987712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.